ANIX
NASDAQ
US
Anixa Biosciences, Inc. - Common Stock
$2.55
▼ $-0.17
(-6.25%)
Vol 69K
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$102.7M
ROE
-63.1%
Margin
-1090.5%
D/E
0.00
Beta
0.53
52W
$2–$5
Wall Street Consensus
10 analysts · Apr 20262
Strong Buy
7
Buy
1
Hold
0
Sell
0
Strong Sell
90.0%
Buy Rating
Price Chart
Similar Stocks
PYXS
Pyxis Oncology Inc
$71.6M
RCEL
AVITA Medical Inc
$105.2M
MCRB
Seres Therapeutics Inc
P/E 25.0
$134.6M
GOSS
Gossamer Bio Inc
$717.5M
HURA
TuHURA Biosciences Inc
$45.9M
ATYR
aTyr Pharma Inc
$76.7M
FBIO
Fortress Biotech Inc
P/E 28.5
$113.6M
GANX
Gain Therapeutics Inc
$123.8M
INO
Inovio Pharmaceuticals Inc
$119.5M
SERA
Sera Prognostics Inc
$113.9M
Earnings
Beat rate: 80.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.10 | $-0.08 | +$0.02 |
| Dec 2025 | $-0.09 | $-0.09 | $0.00 |
| Sep 2025 | $-0.09 | $-0.07 | +$0.02 |
| Jun 2025 | $-0.10 | $-0.09 | +$0.01 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… | 2026-0… |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Net Income | — | — | -$3.2M | -$2.8M | -$2.3M | -$2.7M | -$2.6M |
Fundamentals Trend
| Metric | 2025-07-31 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -63.0% | -64.1% | -63.0% | -63.0% | -63.0% | -63.0% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -1090.5% | -1090.5% | -1090.5% | -1090.5% | -1090.5% |
| Gross Margin | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 8.45 | 8.88 | 8.45 | 8.45 | 8.45 | 8.45 |
Key Ratios
ROA (TTM)
-59.2%
P/S (TTM)
489.05
P/B
5.6
EPS (TTM)
$-0.34
52W High
$5.46
52W Low
$2.07
$2.07
52-Week Range
$5.46
Financial Health
Free Cash Flow
-$2.6M
Net Debt
-$1.4M
Cash
$1.5M
Total Debt
$193K
As of Jan 31, 2026
How does ANIX compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
ANIX valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
489.1
▲
3706%
above
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
5.6
▲
129%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
ANIX profitability vs Biotechnology peers
ROE
-63.1%
▲
6%
above
peers
(-67.3%)
vs Peers
vs Industry
In line
Net margin
-1090.5%
▼
280%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
100.0%
▲
27%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-59.2%
▼
27%
below
peers
(-46.7%)
vs Peers
vs Industry
Below avg
ANIX financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
8.5
▲
90%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
0.5
▼
46%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
ANIX fundamentals radar
ANIX
Peer median
Industry
ANIX profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
ANIX vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
BASKIES ARNOLD M
Director · Jan 28
10000 shs
Last 90 days
Top Holders
Top 5: 10.13%Vanguard Group Inc
4.35%
$3.7M
Laird Norton Wetherby Trust…
1.75%
$1.5M
D.A. Davidson & Co.
1.61%
$1.4M
UBS Group AG
1.37%
$1.2M
Geode Capital Management, L…
1.05%
$895K
As of Dec 31, 2025